

## 해외 바이오의약품 임상 현황 (2020.11.09~2020.11.15)

한국바이오의약품협회, 2020.11.17  
출처: ClinicalTrials.gov

### ○ 미국 21건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04626583	Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells	Mesenchymal Stromal Cells Cornea Safety Corneal Defect	Biological: Allogeneic MSC	University of Illinois at Chicago United States Department of Defense	Phase 1
NCT04583423	A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)	Nonalcoholic Steatohepatitis	Drug: MK-3655 Drug: Placebo	Merck Sharp & Dohme Corp.	Phase 2
NCT04552223	Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma	Metastatic Uveal Melanoma	Drug: Nivolumab Drug: Relatlimab	Jose Lutzky, MD Bristol-Myers Squibb University of Miami	Phase 2
NCT04533464	MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome	Trauma Adult Stem Cells	Biological: MultiStem Biological: Placebo	Athersys, Inc Memorial Hermann Hospital United States Department of Defense	Phase 2
NCT04506073	Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD	Parkinson's Disease	Drug: MSC+placebo Drug: MSC Drug: Placebo	The University of Texas Health Science Center, Houston Michael J. Fox Foundation for Parkinson's Research	Phase 2
NCT04465760	Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis	Lymphoma Malignant Solid Neoplasm Plasma Cell Myeloma	Drug: Xisomab 3G3	OHSU Knight Cancer Institute National Heart, Lung, and Blood Institute (NHLBI) Oregon Health and Science University	Phase 2
NCT04370509	Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery	Metastatic Clear Cell Renal Cell Carcinoma Recurrent Clear Cell Renal Cell Carcinoma Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Clear Cell Renal Cell Carcinoma	Drug: Axitinib (VEGF-TKI) Procedure: Cyto-reductive Nephrectomy (CN) Procedure: Metastasectomy (MET) Biological: Pembrolizumab	University of California, San Francisco Merck Sharp & Dohme Corp.	Phase 2
NCT04303845	Erenumab For Treatment of Hemicrania Continua	Hemicrania Continua	Drug: Erenumab	Mayo Clinic	Phase 2
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adult Diffuse Large Cell Lymphoma Anaplastic Large Cell Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Polymorphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma Hematopoietic and Lymphoid Cell Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporine Biological: Filgrastim Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation Drug: Treosulfan	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04119830	Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer	Metastatic Colorectal Adenocarcinoma Microsatellite Stable Mismatch Repair Proficient Refractory Colorectal Adenocarcinoma Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Unresectable Colorectal Carcinoma	Biological: Pembrolizumab Other: Questionnaire Administration Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) AIM BioPharma	Phase 2
NCT04566445	HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005	Dry Age-related Macular Degeneration	Drug: GT005: Dose 1 Drug: GT005: Dose 2	Gyroscope Therapeutics	Phase 2
NCT04626791	Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma	Mantle Cell Lymphoma	Drug: Acalabrutinib Drug: Bortezomib Drug: Cyclophosphamide Drug: Cytarabine Drug: Doxorubicin Hydrochloride Drug: Prednisone Biological: Rituximab Biological: Rituximab and Hyaluronidase Human	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2
NCT04585776	A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes	Type 1 Diabetes	Drug: LY900014 Drug: Insulin Degludec	Eli Lilly and Company	Phase 2
NCT04569435	Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: ANX005	Annexon, Inc Worldwide Clinical Trials	Phase 2
NCT04502082	Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)	Hepatocellular Carcinoma Liver Cancer Liver Neoplasms Metastatic Liver Cancer	Biological: ET140203 autologous T cell product	Eureka Therapeutics Inc.	Phase 1 Phase 2
NCT04524871	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Drug: Tocilizumab	Hoffmann-La Roche	Phase 1 Phase 2
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2
NCT04619797	A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer (NSCLC)	Drug: Tiragolumab Drug: Atezolizumab Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Tiragolumab Matching Placebo Drug: Pembrolizumab	Hoffmann-La Roche	Phase 2
NCT04569032	A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	Peripheral T-cell Lymphoma	Drug: brentuximab vedotin Drug: cyclophosphamide Drug: doxorubicin Drug: prednisone	Seagen Inc.	Phase 2
NCT04309474	A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke	Acute Ischemic Stroke	Drug: Elezanumab Drug: Placebo	AbbVie	Phase 2
NCT04606381	A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies	Advanced Solid Malignancies	Drug: Ami-LC-MD Drug: Ami-LC Drug: Ami-HC Drug: Ami-HC-CF	Janssen Research & Development, LLC	Phase 1

## 해외 바이오의약품 임상 현황 (2020.11.09~2020.11.15)

한국바이오의약품협회, 2020.11.17  
출처: ClinicalTrials.gov

### ○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04502966	Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction	Allergic Rhinoconjunctivitis Grass Pollen Allergy	Biological: Dupixent® Biological: Grazax® Drug: Dupixent® Placebo Drug: Grazax® Placebo	National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN) ALK-Abelló A/S Regeneron Pharmaceuticals PPD Rho Federal Systems Division, Inc.	Phase 2
NCT04606381	A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies	Advanced Solid Malignancies	Drug: Ami-LC-MD Drug: Ami-LC Drug: Ami-HC Drug: Ami-HC-CF	Janssen Research & Development, LLC	Phase 1

### ○ 프랑스 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04524871	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Drug: Tocilizumab	Hoffmann-La Roche	Phase 1  Phase 2
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2
NCT04605094	Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis	Atopic Dermatitis	Biological: Benralizumab Biological: Placebo / Benralizumab	AstraZeneca qvia Pty Ltd	Phase 2

### ○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04619797	A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer (NSCLC)	Drug: Tiragolumab Drug: Atezolizumab Drug: Pemetrexed Drug: Carboplatin Drug: Cisplatin Drug: Tiragolumab Matching Placebo Drug: Pembrolizumab	Hoffmann-La Roche	Phase 2
NCT04566445	HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005	Dry Age-related Macular Degeneration	Drug: GT005: Dose 1 Drug: GT005: Dose 2	Gyroscope Therapeutics	Phase 2

### ○ 중국 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04560894	SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: SCT-I10A Drug: SCT510 Drug: Sorafenib 200mg	Sinocelltech Ltd.	Phase 2 Phase 3
NCT04613674	A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)	Triple Negative Breast Cancer	Drug: Camrelizumab Plus Chemotherapy Drug: placebo+chemotherapy	Jiangsu HengRui Medicine Co., Ltd.	Phase 3
NCT04603846	A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma	Advanced Urothelial Carcinoma	Drug: anti-PD-L1 antibody Drug: albumin bound paclitaxel	Lee's Pharmaceutical Limited	Phase 1
NCT04465734	A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC	Hepatocellular Carcinoma (HCC)	Drug: HLX10 Drug: HLX04 Drug: Sorafenib	Shanghai Henlius Biotech	Phase 3
NCT04389177	Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC	Esophageal Squamous Cell Carcinoma Stage III	Drug: Pembrolizumab Injection [Keytruda]	Tianjin Medical University Cancer Institute and Hospital	Phase 2
NCT04540211	A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma	Esophageal Cancer	Drug: Atezolizumab Drug: Tiragolumab Drug: Paclitaxel Drug: Cisplatin Drug: Atezolizumab Matching Placebo Drug: Tiragolumab Matching Placebo	Hoffmann-La Roche	Phase 3
NCT04524871	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	Advanced Liver Cancers	Drug: Atezolizumab Drug: Bevacizumab Drug: Tiragolumab Drug: Tocilizumab	Hoffmann-La Roche	Phase 1 Phase 2

### ○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04619420	A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	Alzheimer Disease Cognitive Dysfunction Dementia	Drug: JNJ-63733657 Drug: Placebo	Janssen Research & Development, LLC	Phase 2